- American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
- Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
- Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
- NeuroCap and NeuroEEG device patents approved in U.S., Europe and China
With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market.
According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues.
As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions.
Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets.
The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices.
Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry.
For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
